Navigation Links
Study: New genes identified may unlock mystery of keloid development
Date:5/29/2014

DETROIT Researchers at Henry Ford Hospital in Detroit have uncovered previously unidentified genes that may be responsible for keloid scarring, a discovery that could unlock the mystery of keloid development and provide insight for more effective treatment.

"Much of the uncertainty surrounding keloids is rooted in there being no known cause for their development," says study lead author Lamont R. Jones, M.D., vice chair, Department of Otolaryngology-Head and Neck Surgery at Henry Ford.

"But it is believed that keloids have a genetic component given the correlation with family history, prevalence in twins, and its predisposition in darker skin."

Results from the study were presented this week at the American Academy of Facial Plastic and Reconstructive Surgery's 11th International Symposium in New York City.

Keloid scars form raised, firm skin areas that may become itchy, tender, and painful. Unlike regular scars, keloids do not subside over time and often extend outside the wound site.

Keloids most often occur on the chest, shoulders, earlobes (following ear piercing), upper arms and cheeks. The lowest rates of keloid formation have been documented in albinos and the highest seen in dark skinned individuals, especially in the African-American population.

Treatment for keloids includes cortisone injections, pressure dressings, silicone gels, surgery, cryosurgery (freezing), laser treatment, or radiation therapy. A combination of treatments may be used, depending on the individual.

In some cases, keloids return after treatment, up to 50 to 100 percent of the time.

For the Henry Ford study, Dr. Jones and his colleagues used six fresh keloid samples and six fresh normal skin samples in which genome-wide profiling was previously done. This effort identified 190 statistically significant regions of DNA that were mapped to 152 keloid specific genes.

The 152 genes were uploaded into the Ingenuity Pathway Analysis software, which integrates genes and molecules that are part of the same biological functions or regulatory networks interacting together.

Among 152 unique genes, the researchers found 10 genes that demonstrated an increase of the cellular components and regulatory pathways important to the biological processes in keloid development.

In all, the researchers were able to show that certain keloid genomes are present in known bionetwork pathways involved in critical biological functioning and signaling events in the cell.

Dr. Jones notes the importance of this new information and how it can be used to "further refine the screening process for biological significance in hopes of better understanding the pathogenesis and molecular targeted therapy for keloid disease."

"By identifying the genetic cause, it may be possible to develop better treatments for keloids in the near future," he says.


'/>"/>
Contact: Krista Hopson
khopson1@hfhs.org
313-874-7207
Henry Ford Health System
Source:Eurekalert  

Related medicine news :

1. Study: Women not getting enough exercise; at risk of developing metabolic syndrome
2. Study: Insomnia takes toll on tinnitus patients
3. Study: No link between depression, nasal obstruction
4. Study: More Pre-Teens Get Vaccines When Middle Schools Require Them
5. Study: Kids Who Sleep in Parents Bed Less Likely to Be Overweight
6. OHSU study: Misdiagnosis of MS is costing health system millions per year
7. UW study: Sleep apnea associated with higher mortality from cancer
8. Study: Heart damage after chemo linked to stress in cardiac cells
9. STeleR study: Telerehab improves functioning after stroke
10. Study: Willingness to be screened for dementia varies by age but not by sex, race or income
11. Study: 21 percent of newly admitted nursing home residents sustain a fall during their stay
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study: New genes identified may unlock mystery of keloid development
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... the California Dental Association, today announced it has signed a letter of intent ... Corporation (DBC) and Northwest Dentists Insurance Company (NORDIC). , Started by dentists 36 ...
(Date:4/28/2016)... ... 28, 2016 , ... CastCoverz!, America’s #1 trusted brand for ... oldest waterproof cast protector . As the largest one-stop, orthopedic shop, CastCoverz! ... daily, night, weatherproof and waterproof covers for most orthopedic devices, including but not ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... the organization’s most successful events, attracting medical professionals from around the globe who ... networking events. , Opening Ceremonies Sunday, April 17 included the introduction of the ...
(Date:4/28/2016)... ... April 28, 2016 , ... In many parts of the world, ... childhood mortality. This is particularly true in underdeveloped parts of Africa where clean sources ... New England’s campus in Tangier, Morocco, will examine this global health issue and consider ...
(Date:4/28/2016)... ... 28, 2016 , ... Cognizin® Citicoline is one of three ... the Healthy Ageing category, Cognizin® is being considered for this prestigious honor due ... include everything from antioxidants, lipids, proteins, and botanicals. NutraIngredients will choose a winner ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ... on the development of oral drug delivery systems, announced today ... conference, presented by Joseph Gunnar & Co. LLC, ... York . Nadav Kidron , CEO of Oramed, ... Presentation Details:   PIONEERS 2016, presented by ...
(Date:4/28/2016)... , April 28, 2016  ValGenesis, Inc., ... Management Solutions (VLMS) today announced that a ... for sufferers of chronic kidney failure has ... manage their corporate validation process. The global ... software solution to manage their validation processes ...
(Date:4/28/2016)... , April 28, 2016 ... H1 2016" is a report that provides an ... strengthen R&D pipelines by identifying new targets and ... Company Profiles discussed in this H1 2016 ... Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx ...
Breaking Medicine Technology: